Gains, losses and complex karyotypes in
β
Sara Alvarez; Juan C. Cigudosa
π
Article
π
2005
π
John Wiley and Sons
π
English
β 164 KB
Complex karyotypes are seen in approximately 15% of de novo MDS/AML and in up to 50% of therapy-related MDS/AML. These patients represent a therapeutic challenge for which no current treatment approach is satisfactory. Therefore, a large number of genetic studies using cytogenetic molecular techniqu